---
title: "Ersodetug (RZ358) in Tumor hyperinsulinism: Definition and etiology"
description: "Formulary evidence on Ersodetug (RZ358) in Tumor hyperinsulinism: Definition and etiology. Topics: Tumor hyperinsulinism as defined by the manufacturer: islet cell and non-islet cell tumors, Tumor types named by the manufacturer: insulinoma and non-islet cell tumors, Tumor hyperinsulinism as defined in the first expanded access report, Insulinoma: definition and tumor location, and 4 further topics. 8 evidence topics quoted from 10 sources."
canonical: "https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/product-information-and-disease-description/definition-and-etiology"
published: "2026-11-15T20:24:18-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Ersodetug (RZ358) in Tumor hyperinsulinism: Definition and etiology

<a id="heading-2.2.1.1"></a>

## 2.2.1.1 Definition and Etiology

<a id="topic-2.2.1.1-1"></a>

### Tumor hyperinsulinism as defined by the manufacturer: islet cell and non-islet cell tumors

> “Tumor hyperinsulinism (HI) is a rare disease that may be caused by two distinct types of tumors: islet cell tumors (ICTs) and non-islet cell tumors (NICTs), both of which lead to hypoglycemia because of over-activation of the insulin receptor.”
> “Insulinomas are the most common type of ICT and cause hypoglycemia via the overproduction of insulin.”
> “A variety of different NICTs, including hepatocellular carcinoma and soft tissue malignancies (e.g. sarcomas), can cause hypoglycemia by producing and secreting insulin-like paraneoplastic substances, such as variants of IGF-2, that bind to and activate the insulin receptor.”

Source: [Rezolute upLIFT results release (2026)](https://ir.rezolutebio.com/news/detail/389/rezolute-announces-positive-results-from-the-phase-3-uplift-study-in-tumor-hyperinsulinism)

<a id="topic-2.2.1.1-2"></a>

### Tumor types named by the manufacturer: insulinoma and non-islet cell tumors

> “Insulinomas are the most common type of functional ICT and mediate hypoglycemia through excessive insulin production.”
> “NICTs are generally associated with relatively large, solid tumors such as hepatocellular carcinoma, fibrosarcoma and mesothelioma, and can cause hypoglycemia by producing and secreting insulin-like paraneoplastic substances such as IGF-2 or related variants that bind to and activate the insulin receptor.”
> “This form of hypoglycemia can occur in more than 15 different types of tumors.”

Source: [Rezolute Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1509261/000110465926110420/rzlt-20260630x10k.htm)

> “Ultra-rare disease caused by tumors that produce insulin or insulin-like substances such as IGF-2”
> “Malignant insulinomas are the most common ICTs that cause hypoglycemia”
> “Hepatocellular carcinomas (HCC) are the most common NICTs that cause hypoglycemia in addition to several other tumor types including fibrosarcomas and mesotheliomas”
> “Over 16 different tumors have been linked to IGF-2, including liver, stomach, lung, breast, ovary, sarcomas, colorectal, esophageal, and others”

Source: [Rezolute October corporate presentation (2026)](https://www.sec.gov/Archives/edgar/data/1509261/000110465926120205/tm2628517d1_ex99-1.htm)

<a id="topic-2.2.1.1-3"></a>

### Tumor hyperinsulinism as defined in the first expanded access report

> “Tumor hyperinsulinism (tumorHI) occurs when insulin or related paraneoplastic substances produced in excess by tumors stimulate the insulin receptor, leading to excessive signaling and hypoglycemia.”
> “TumorHI arises from two types of neoplasms: pancreatic neuroendocrine tumors (pNETs), i.e. insulinomas, and a variety of other tumors, which can oversecrete forms of IGF-2.”

Source: [Strosberg et al. (2024)](https://rezolutebio.com/wp-content/uploads/2025/10/NANETS-2024-Poster_Final.pdf)

<a id="topic-2.2.1.1-4"></a>

### Insulinoma: definition and tumor location

> “Insulinomas are hormone-producing pancreatic neuroendocrine neoplasms with an estimated incidence of 1 to 4 cases per million per year. Extrapancreatic insulinomas are extremely rare.”
> “More than 99% of insulinomas are located in the pancreas, where its tumor locations are evenly distributed”
> “Approximately 10% of insulinomas present as multiple lesions”

Source: [Hofland et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10940262/)

<a id="topic-2.2.1.1-5"></a>

### Insulinoma: aggressive (malignant) and indolent (benign) forms

> “Approximately 10% to 15% of insulinomas belong to the aggressive category and 85% to 90% can be considered as indolent”
> “Secondary, or metachronous insulin secretion by panNEN that previously were nonsecreting, or secreting other peptide hormones, can also occasionally develop and is generally associated with a poor survival as compared with their non-insulin-secreting counterparts”

Source: [Hofland et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10940262/)

> “Malignancy was defined by distant metastases, positive lymph node(s), T stage of 4, direct invasion into surrounding peripancreatic tissue, or presence of lymphovascular invasion.”
> “A total of 311 patients were identified: 51 malignant and 260 benign.”

Source: [Sada et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/32873371/)

<a id="topic-2.2.1.1-6"></a>

### Insulinoma: hereditary etiology in multiple endocrine neoplasia type 1

> “A total of 5% to 10% of insulinomas are associated with the multiple endocrine neoplasia type 1 (MEN1) syndrome.”
> “The MEN1-related insulinomas may develop as multiple synchronous or metachronous lesions and are generally diagnosed at an earlier age than their sporadic counterparts because of application of the MEN1 screening recommendations”

Source: [Hofland et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10940262/)

<a id="topic-2.2.1.1-7"></a>

### Non-islet cell tumor hypoglycemia: definition

> “Paraneoplastic hypoglycemia, also known as non-islet cell tumor hypoglycemia (NICTH), refers to hypoglycemia caused by or associated with tumors other than insulinoma. A wide range of epithelial, vascular or mesenchymal-origin neoplasms have been linked with NICTH”
> “Most cases of paraneoplastic hypoglycemia are attributed to the tumor's ability to produce insulin-like growth factor 2 (IGF-2) and its precursors, which activate insulin receptors, thereby enhancing glucose utilization”

Source: [Karamanolis et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11342107/)

> “In closing, we replace non-islet-cell tumor hypoglycemia, an outdated and misleading label, with IGF-2-oma, self-explanatory and consistent with names of other hormone-secreting tumors.”

Source: [Dynkevich et al. (2013)](https://pubmed.ncbi.nlm.nih.gov/23671155/)

<a id="topic-2.2.1.1-8"></a>

### Non-islet cell tumor hypoglycemia: associated tumor types

> “The most common tumours associated with IGF‐2‐mediated hypoglycaemia were fibrous tumours (N = 124, 53.2%), followed by non‐fibrous tumours originating from the liver (N = 21, 9%), hemangiopericytoma (N = 20, 8.5%) and mesothelium (N = 11, 4.7%).”

Source: [Ata et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10897872/)

> “we analyzed the medical records of 78 patients with NICTH (M/F 44/34, age 62+/-1.8, range; 9-86 years.) whose serum contained a large amount of big IGF-II. Hepatocellular carcinoma and gastric carcinoma were the most common causes of NICTH.”

Source: [Fukuda et al. (2006)](https://pubmed.ncbi.nlm.nih.gov/16860583/)

> “Among epithelial cancers, hepatocellular carcinomas are the most common, followed by adrenocortical tumors. Vascular tumors like hemangiopericytomas may also be linked to NICTH. In mesenchymal neoplasms, mesotheliomas and fibrosarcomas are the most frequently associated with paraneoplastic hypoglycemia.”

Source: [Karamanolis et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11342107/)

## Related pages
- [Ersodetug (RZ358): Tumor hyperinsulinism](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism.md)
- [Ersodetug (RZ358) in Tumor hyperinsulinism: Terms and abbreviations](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/terms-and-abbreviations.md)
- [Ersodetug (RZ358): Tumor hyperinsulinism](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/executive-summary) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/executive-summary.md)
- [Ersodetug (RZ358) in Tumor hyperinsulinism: Product information and disease description](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/product-information-and-disease-description.md)
- [Ersodetug (RZ358) in Tumor hyperinsulinism: Clinical evidence](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/clinical-evidence.md)
- [Ersodetug (RZ358) in Tumor hyperinsulinism: Economic information and modeling report](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/economics) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/economics.md)
- [Ersodetug (RZ358) in Tumor hyperinsulinism: References](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/references) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/references.md)
